Zhoushi Qiling decoction inhibits proliferation of human prostate cancer cells through IL6/STAT3 pathway

Hongwen Cao1, Yigeng Feng1, Peng Sun1

  • 1Surgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, No. 725 Wanping Road South, Xuhui District, Shanghai 200032, China.

Journal of Cancer
|August 14, 2023
PubMed

Insights

Zhoushi Qiling decoction (ZQD) inhibits advanced prostate cancer progression. This traditional Chinese medicine reduces cell proliferation and tumor growth by blocking the interleukin-6/signal transducer and activator of transcription 3 (IL-6/STAT3) pathway.

Area of Science:

  • Oncology
  • Pharmacology
  • Traditional Chinese Medicine

Background:

  • Prostate cancer is a leading global cancer in men.
  • Advanced prostate cancer (APC) lacks effective pharmacological treatments.
  • Investigating novel therapeutic mechanisms for APC is crucial.

Purpose of the Study:

  • To elucidate the mechanism of Zhoushi Qiling decoction (ZQD) in inhibiting prostate cancer.
  • To evaluate ZQD's effects on prostate cancer cell proliferation and tumor growth.
  • To explore ZQD's impact on the IL-6/STAT3 signaling pathway.

Main Methods:

  • Cell viability (MTT assay) and proliferation (colony formation assay) in PC3 and DU145 cells.
  • Analysis of IL-6/STAT3 pathway components via qRT-PCR and Western blot.
  • In vivo studies using xenograft tumor models.

Main Results:

  • ZQD significantly inhibited IL-6-induced viability and proliferation in prostate cancer cells.
  • ZQD reduced key mRNA and protein levels associated with IL-6/STAT3 signaling (IL-6, STAT3, Bcl2, CyclinD1).
  • ZQD treatment decreased tumor volume, weight, and proliferation in vivo, alongside inhibiting IL-6 and pSTAT3.

Conclusions:

  • ZQD demonstrates significant anti-prostate cancer activity.
  • ZQD effectively reduces cell proliferation and tumor growth.
  • The mechanism involves the inhibition of the IL-6/STAT3 signaling pathway.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K